Dianthus Therapeutics, Inc.
NASDAQ:DNTHBiotechnology
-$1.03 today
- Market cap
- $4.73B
- Beta
- 0.07
- P/E (TTM)
- -343.0
- EPS (TTM)
- -$0.24
Volume 0.84M
Average 0.82M
DNTH Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Dianthus Therapeutics, Inc.NASDAQ: DNTH
Other Income / Expenses · Q2 FY2026 · quarter ended Jun 2026
Other income / expenses grows, but more slowly than its trailing trend
Q2 FY2026 other income / expenses of $11.27M rose 241.6% year over year, behind the +1139.2% change in trailing-twelve-month other income / expenses. Sequentially, it rose 97.7% from the prior quarter. Over 3 fiscal years it compounded at +133.2% a year.
Context
- Other income / expenses amounted to 766.0% of revenue in FY2025, up 495.0 pp from a year earlier.
- Other income / expenses increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +241.6% toward the trailing-twelve-month pace of +1139.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- 15.6M USD
- Year-over-year change
- -7.7%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 15.6M | -7.7% |
| FY2024 | 2024-12-31 | 16.9M | +265.8% |
| FY2023 | 2023-12-31 | 4.62M | +275.8% |
| FY2022 | 2022-12-31 | 1.23M | +5443.5% |
| FY2021 | 2021-12-31 | (23K) | — |
Other Income / Expenses vs competitors
How DNTH compares with its peers on the latest reported figures
- DNTH's LTM Jun 2026 other income / expenses of $187.94M is the highest of the 10 companies compared; the peer median is $8.98M.
- Its year-over-year change of +1139.2% is the highest of 10, against a peer median of -60.4%.
- Other income / expenses amounts to 9870.5% of revenue for DNTH, versus a peer median of 271.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $187.94M | +1139.2% | +133.2% | 9870.5% | |
| LTM Sep 2026 | $21.05M | -14.7% | — | 296.6% | |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $18.29M | -91.0% | +350.3% | 247.2% |
| LTM Jun 2026 | $13.87M | -22.0% | +104.7% | — | |
| LTM Mar 2026 | $11.83M | +129.2% | — | 22.0% | |
| LTM Mar 2026 | $8.98M | -61.4% | +194.6% | — | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | $5M | -50.6% | +65.3% | — |
| FY2025 | $2.79M | -60.4% | +22.4% | 4360.9% | |
| LTM Mar 2026 | -$67.43M | -67.3% | — | 29.0% | |
| LTM Mar 2026 | -$69.65M | -583.2% | — | 3924.1% | |
| Peer median (excluding DNTH) | $8.98M | -60.4% | +104.7% | 271.9% | |
Competitors are the stored peer set for DNTH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.48M | 6.42M | 2.83M | 6.24M | 2.04M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 1.48M | 6.42M | 2.83M | 6.24M | 2.04M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research & Development | 12.61M | 29.38M | 32.84M | 83.11M | 145.64M |
| Selling, General & Admin | 1.96M | 6.74M | 18.16M | 24.99M | 34.33M |
| Operating Expenses | 14.56M | 36.12M | 51M | 108.1M | 179.97M |
| Depreciation & Amortization | 2.02M | 147K | 355K | 412K | 428K |
| EBITDA | (11.09M) | (28.33M) | (43.2M) | (84.56M) | (161.91M) |
| EBITDA Margin | -751.3% | -441.5% | -1528.7% | -1356.2% | -7952.3% |
| Operating Income | (13.09M) | (29.71M) | (48.17M) | (101.86M) | (177.93M) |
| Operating Margin | -886.6% | -462.9% | -1704.7% | -1633.7% | -8739.3% |
| Interest Income | 100K | 1.15M | 4.76M | 17.37M | 16.12M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (23K) | 1.23M | 4.62M | 16.9M | 15.6M |
| Income Before Tax | (13.11M) | (28.48M) | (43.56M) | (84.97M) | (162.34M) |
| Pre-Tax Margin | -888.1% | -443.8% | -1541.2% | -1362.8% | -7973.3% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (13.11M) | (28.48M) | (43.56M) | (84.97M) | (162.34M) |
| Net Margin | -888.1% | -443.8% | -1541.2% | -1362.8% | -7973.3% |
| EPS (Basic) | (3.82) | (7.60) | (8.45) | (2.55) | (4.20) |
| EPS (Diluted) | (3.82) | (7.60) | (8.45) | (2.55) | (4.20) |
| Weighted Avg Shares | 3.43M | 3.75M | 5.15M | 33.31M | 37.79M |
| Weighted Avg Shares (Diluted) | 3.43M | 3.75M | 5.15M | 33.31M | 37.79M |
Dianthus Therapeutics, Inc.
NASDAQ:DNTH
Intrinsic Alpha fair value
Locked
Current Price
$83.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.